No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
CNTX Context Therapeutics
- 1.4101
- +0.0301+2.18%
Close Apr 26 16:00 ET
- 1.3800
- -0.0301-2.13%
Post 18:41 ET
22.51MMarket Cap-940P/E (TTM)
1.4498High1.3700Low20.13KVolume1.4200Open1.3800Pre Close28.56KTurnover0.15%Turnover RatioLossP/E (Static)15.97MShares1.690052wk High1.90P/B19.58MFloat Cap0.470052wk Low--Dividend TTM13.89MShs Float10.8700Historical High--Div YieldTTM5.78%Amplitude0.4700Historical Low1.4180Avg Price1Lot Size
Full Hours
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Buy Rating on Context Therapeutics's CTIM-76 Bolstered by Market Validation and Competitive Edge
Express News | Context Therapeutics Submitted An FDA Investigational New Drug To Begin Phase 1 Dose Escalation And Expansion Trial Of CTIM-76 For Claudin 6-Positive Gynecologic And Testicular Cancers
Context Therapeutics Advances Cancer Trial With FDA Submission
Context Therapeutics Submits IND Application to Evaluate CTIM-76 in Claudin 6-Positive Cancers
Important Regulatory Milestone Supports Next Phase of CTIM-76 DevelopmentPHILADELPHIA, April 01, 2024 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. ("Context" or the "Company") (Nasdaq: CNTX), a bio
Buy Rating Justified by Advances in T Cell Engagers and Context Therapeutics' Strategic Drug Positioning
Context Therapeutics Price Target Cut to $4.00/Share From $5.00 by HC Wainwright & Co.
Context Therapeutics Price Target Cut to $4.00/Share From $5.00 by HC Wainwright & Co.
Comments
Update
$Context Therapeutics(CNTX.US$ Important Regulatory Milestone Supports Next Phase of CTIM-76 Development
PHILADELPHIA, April 01, 2024 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. ("Context" or the "Company") (Nasdaq: CNTX), a biopharmaceutical company advancing medicines for solid tumors, today announced that on March 28, 2024, the Company submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration to begin a first-in-human clinical study of CTIM-76. ...
PHILADELPHIA, April 01, 2024 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. ("Context" or the "Company") (Nasdaq: CNTX), a biopharmaceutical company advancing medicines for solid tumors, today announced that on March 28, 2024, the Company submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration to begin a first-in-human clinical study of CTIM-76. ...
1
$Kintara Therapeutics(KTRA.US$ 2023 🎆
what a great day trading - winning made simple
$Context Therapeutics(CNTX.US$
$cbdMD(YCBD.US$
$China SXT Pharmaceuticals(SXTC.US$
$China Green Agriculture(CGA.US$
multiple winners 🏆💪🏻
Apextradez 🔗 up with me 🤩 supporters get free access to mega elite alerts 🫵🏻 can win if you want to get serious in 2024 and winning is your goal
what a great day trading - winning made simple
$Context Therapeutics(CNTX.US$
$cbdMD(YCBD.US$
$China SXT Pharmaceuticals(SXTC.US$
$China Green Agriculture(CGA.US$
multiple winners 🏆💪🏻
Apextradez 🔗 up with me 🤩 supporters get free access to mega elite alerts 🫵🏻 can win if you want to get serious in 2024 and winning is your goal
+3
1
$Context Therapeutics (CNTX.US)$ @Alvinnnnnnn89 Hi, Master Alvin, this stock has the potential to move further?
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg